The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.
about
Hepatic Encephalopathy: An Update on the Pathophysiology and Therapeutic Options.The patient buddy app can potentially prevent hepatic encephalopathy-related readmissions.Fecal Microbiota Transplant from a Rational Stool Donor Improves Hepatic Encephalopathy: A Randomized Clinical Trial.Readmission in Cirrhosis: a Growing Problem.Gender-Specific Differences in Baseline, Peak, and Delta Serum Creatinine: The NACSELD Experience.Predictors of Early Readmission in Patients With Cirrhosis After the Resolution of Bacterial Infections.The impact of carbapenem resistance on clinical deterioration and mortality in patients with liver disease.A Karnofsky performance status-based score predicts death after hospital discharge in patients with cirrhosis.Healthcare utilization after liver transplantation is highly variable both among centers and recipients.The brain gets its say: Hepatic encephalopathy and its evolving role in transplant priority.Symptom Domain Groups of the Patient-Reported Outcomes Measurement Information System Tools Independently Predict Hospitalizations and Re-hospitalizations in Cirrhosis.Hospital readmissions in decompensated cirrhotics: Factors pointing toward a prevention strategy.Improving Quality of Care in Patients with Liver Cirrhosis.Frailty as Tested by Gait Speed is an Independent Risk Factor for Cirrhosis Complications that Require Hospitalization.Low skeletal muscle mass is associated with increased hospital costs in patients with cirrhosis listed for liver transplantation-a retrospective study.Palliative care in decompensated cirrhosis: A review.Nursing care of patients with chronic liver diseases: Time for action.Assessment of the Spectrum of Hepatic Encephalopathy: A Multi-Center Study.Hospital Cirrhosis Volume and Readmission in Patients with Cirrhosis in California.Incidence and cost analysis of hospital admission and 30-day readmission among patients with cirrhosis.Gut microbial RNA and DNA analysis predicts hospitalizations in cirrhosis.Exploring opportunities to prevent cirrhosis admissions in the emergency department: A multicenter multidisciplinary survey.Systematic Review of the Economic Burden of Overt Hepatic Encephalopathy and Pharmacoeconomic Impact of Rifaximin.Paracentesis in cirrhotics is associated with increased risk of 30-day readmission.Design of the Prospective Real-world Outcomes Study of hepatic encephalopathy Patients' Experience on Rifaximin-α (PROSPER): an observational study among 550 patients
P2860
Q33805285-A588D073-F016-433D-AD49-FB387FDCDD2CQ38724113-A9473EB9-13AF-4CF9-8CA2-83E81F4F333DQ38740977-1F6CACA0-3189-4846-8CC5-BBB4D07B9929Q38796236-C4D61491-2482-49F6-803B-990197EE59A4Q39063021-113FAC40-BDFC-4687-89FD-F9120982A347Q40074799-4DC532E9-ADD5-44FE-975F-8E3D999A0ADBQ40265624-BF9B7827-50D1-42BF-9514-BB13B4703BBDQ40519953-513A252C-A0EA-4CC4-9D7E-5D49026EA9EDQ42696541-02AC69EB-F2B4-4931-AA88-E13CD7BA5048Q45040034-3848A764-61E6-42F3-B479-B89E96B3C12AQ45053969-7006F824-D5AB-430B-ABB5-AFDAFA525B24Q47105501-DCABD883-ABB4-483C-BDDE-11D3B9F7AA62Q47141166-29C747FA-1C35-450A-AB2B-8D04A8CC281EQ48043212-25590408-049F-48B3-A4F5-3676AA4CC6D4Q48130444-8EF714B4-63CA-421C-827F-B25F30687CD2Q48349992-0069CF65-EAD7-46D3-9CF9-6932F4EB14F1Q48360473-3EAA819D-2BF2-4F66-AA86-5B8259638AE6Q49850243-6AD5180E-9FDE-4899-A075-A8817BC9E281Q49862219-AF7FD0FD-E70D-49ED-8E37-1872764B39D3Q51366510-9BF086C2-E2AE-4250-9169-55AF9392B645Q54260378-AD3D24F6-D64B-4BFC-B752-1C813DFBBB65Q55224804-2E5F7633-A33A-4DAE-8453-54BE0BAF659AQ55381916-0E7BEC3F-F938-4CCE-9F92-E418F35BE626Q55505577-92E3A5D9-A2CD-49A0-A439-0B8B3EF3178AQ57148620-5801668F-B823-45B4-A171-43824E277D01
P2860
The 3-month readmission rate remains unacceptably high in a large North American cohort of patients with cirrhosis.
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The 3-month readmission rate r ...... rt of patients with cirrhosis.
@en
type
label
The 3-month readmission rate r ...... rt of patients with cirrhosis.
@en
prefLabel
The 3-month readmission rate r ...... rt of patients with cirrhosis.
@en
P2093
P2860
P356
P1433
P1476
The 3-month readmission rate r ...... rt of patients with cirrhosis.
@en
P2093
Benedict Maliakkal
Florence Wong
Guadalupe Garcia-Tsao
Hugo Vargas
Jacqueline G O'Leary
Jasmohan S Bajaj
Leroy R Thacker
Michael B Fallon
North American Consortium for the Study of End-Stage Liver Disease
Patrick S Kamath
P2860
P304
P356
10.1002/HEP.28414
P407
P577
2015-12-21T00:00:00Z